COUNCIL RECOMMENDS APPROVAL OF CRESTOR IN JAPAN AstraZeneca announced today that the Pharmaceuticals Affairs Council has recommended that the Japanese Ministry of Health, Labour and Welfare (MHLW) approve CRESTOR TM (rosuvastatin) in Japan at a dose range of 2.5-20 mg for the treatment of hypercholesterolaemia. The Council’s recommendation is contingent on final agreement of a post marketing surveillance programme. The recommended starting dose of 2.5 mg is in line with normal clinical practice in Japan where, compared to the western world, lower dose
ASTRAZENECA BOARD ANNOUNCEMENT AstraZeneca PLC today confirms the appointment of Louis Schweitzer as non-executive Chairman with effect from 1 January 2005. Percy Barnevik will retire from the Board as Chairman and a Director on 31 December 2004. The appointment of Louis Schweitzer as Chairman was anticipated in the announcement of his appointment as a non-executive Director on 11 March 2004.
EUROPEAN MUTUAL RECOGNITION PROCEDURE APPROVES ASTRAZENECA’S ATACAND® FOR THE TREATMENT OF CHRONIC HEART FAILURE AstraZeneca today announced that the European Mutual Recognition Variation Procedure (MRP) evaluating the use of Atacand® (candesartan cilexetil), a selective angiotensin receptor blocker (ARB) in the treatment of chronic heart failure (CHF) has been completed. Atacand, already a well established antihypertensive therapy, is now indicated for the treatment of patients with heart failure and impaired left ventricle systolic function. The UK was the MRP Reference Member State for marketing approval across a
Monday, 29 November 2004
NEXIUM RECEIVES FDA APPROVAL FOR RISK REDUCTION OF NSAID-ASSOCIATED STOMACH ULCERS AstraZeneca today announced that a new indication for its prescription proton pump inhibitor Nexium® (esomeprazole magnesium) has been approved by the US Food and Drug Administration (FDA). Nexium is now also indicated for reducing the risk of gastric (stomach) ulcers developing among at risk patients on continuous therapy with non-steroidal anti-inflammatory drugs (NSAIDs). The FDA also issued an approvable letter for the indication of the healing of gastric ulcers associated with NSAIDs therapy.
This website is intended for people seeking information on AstraZeneca's International business. We also have national business sites; links to these are under 'Other AZ websites' at the top of the page.